Year :

Legend Biotech Announces Chief Executive officer Transition

SOMERSET, N.J.–(BUSINESS WIRE)—August 2, 2020—Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced that its Board of Directors has appointed Dr. Frank Zhang to serve as Chief Executive Officer, effective immediately. Dr. Zhang will succeed […]

Aug 02, 2020

Legend Biotech Corporation Announces Closing of Initial Public Offering

SOMERSET, NJ – June 9, 2020 – Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced the closing of its initial public offering of 21,188,750 American depositary shares (ADSs), each representing two ordinary shares, at […]

Jun 09, 2020

Legend Biotech Announces Three New Appointments to the Board of Directors

SOMERSET, NJ – June 9, 2020 – Legend Biotech (NASDAQ: LEGN) announced today that it has appointed Dr. Corazon (Corsee) Dating Sanders, Dr. Darren Ji, and Mr. Philip Yau to the company’s Board of Directors. Dr. Sanders joined the Legend Biotech Board of Directors in May 2020. She has over 25 years of experience in […]

Jun 09, 2020

Legend Biotech Corporation Announces Pricing of Initial Public Offering

SOMERSET, NJ – June 5, 2020 – Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced the pricing of its initial public offering of 18,425,000 American depositary shares (ADSs), each representing two ordinary shares, at […]

Jun 05, 2020

Updated Results from Phase 1b/2 Study of BCMA CAR-T Therapy JNJ-4528 Shows Early, Deep and Durable Responses in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma

Longer-term follow up data (median of 11.5 months) from the Phase 1b portion of the CARTITUDE-1 study demonstrated 100% overall response rate, 86% stringent complete response rate and a 9 month progression free survival rate of 86%. Somerset, N.J., May 13, 2020 – Legend Biotech Corporation (“Legend”) announced today updated results from the Janssen Pharmaceutical […]

May 13, 2020

Thank you for your interest in learning more about Legend Biotech.

Media Relations & Communications

media@legendbiotech.com

close

You are about to leave LegendBiotech.com

We use cookies to improve your experience on our website, measure performance, understand our audience, for advertising and support purposes. You can always change your preferences or opt out from our use of cookies.